<DOC>
	<DOCNO>NCT00234052</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin pemetrexed disodium , work different way stop growth tumor cell , either kill cell stop dividing . Pemetrexed disodium may also stop growth tumor cell block enzymes need cell growth . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . Giving carboplatin pemetrexed disodium together bevacizumab may kill tumor cell . PURPOSE : This phase II trial study well give carboplatin pemetrexed disodium together bevacizumab work treat patient stage IIIB , stage IV , recurrent non-small cell lung cancer .</brief_summary>
	<brief_title>Carboplatin , Pemetrexed Disodium , Bevacizumab Treating Patients With Stage IIIB , Stage IV , Recurrent Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine median time disease progression patient stage IIIB IV recurrent non-squamous cell non-small cell lung cancer treat carboplatin , pemetrexed disodium , bevacizumab . Secondary - Determine response rate duration response patient treat regimen . - Determine toxic effect regimen patient . - Determine overall survival patient treat regimen . OUTLINE : This multicenter study . Patients receive pemetrexed disodium IV 10 minute , carboplatin IV 30 minute , bevacizumab IV 30-90 minute day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion 6 course , patient complete response , partial response , stable disease continue receive pemetrexed disodium bevacizumab absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically* cytologically* confirm nonsmall cell lung cancer Any histology , except squamous cell carcinoma , allow Mixed tumor categorize predominant cell type unless small cell element present , case patient ineligible No histology close proximity major vessel cavitation NOTE : *Histologic cytologic element may establish metastatic tumor aspirate biopsy Meets 1 follow stage criterion : Stage IIIB disease ( malignant pleural effusion ) Stage IV disease Recurrent disease Measurable nonmeasurable disease No known CNS metastases CT scan MRI PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 No history hemorrhagic disorder Hepatic Bilirubin &lt; 1.5 mg/dL AST ALT &lt; 5 time upper limit normal INR &lt; 1.5 PTT normal Renal Creatinine clearance ≥ 45 mL/min Urine protein : creatinine ≤ 1.0 spot urinalysis Cardiovascular No myocardial infarction within past 6 month No New York Heart Association class IIIV congestive heart failure No unstable angina pectoris No serious cardiac arrhythmia require medication No stroke within past 6 month No peripheral vascular disease ≥ grade 2 No uncontrolled hypertension ( i.e. , blood pressure ≥ 150/100 mm Hg ) Patients history hypertension allow provide blood pressure well control stable regimen antihypertensive therapy No history thrombotic disorder No clinically significant cardiovascular disease Pulmonary No history gross hemoptysis , define bright red blood ½ teaspoon Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Must willing able take daily oral folic acid , intermittent vitamin B_12 injection , corticosteroid premedication No ongoing active infection No serious , nonhealing wound , ulcer , bone fracture No abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 6 month No psychiatric illness social situation would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy More 3 week since prior immunotherapy Chemotherapy No prior systemic chemotherapy Endocrine therapy More 3 week since prior hormonal therapy Radiotherapy See Disease Characteristics More 3 week since prior radiotherapy Surgery More 4 week since prior major surgery More 1 week since prior minor surgery , fine needle aspiration , core biopsy No concurrent major surgery Other Recovered prior therapy More 4 week since prior concurrent participation another experimental drug study No aspirin nonsteroidal antiinflammatory drug ( NSAID ) 2 day 2 day pemetrexed disodium infusion ( 5 day 2 day pemetrexed disodium infusion NSAIDs long halflife [ e.g. , naproxen , rofecoxib , celecoxib ] ) No concurrent therapeutic anticoagulation Concurrent prophylactic anticoagulation venous access device allow provided requirement INR PTT meet No concurrent administration follow : Chronic daily treatment aspirin ( &gt; 325 mg per day ) NSAIDs know inhibit platelet function , include follow : Dipyridamole Ticlopidine Clopidogrel Cilostazol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
</DOC>